The finest biopharmaceutical research in the world helped wrestle HIV AIDS down into a manageable disease . Now , it is giving us the same opportunity against hepatitis C and many more diseases . e need to move forward , and let the harrowing experience of HIV AIDS patients inform our continued war against diseases like hepatitis C . And simple economics will remind us that , while investments at first may seem challenging , the prescription drug life cycle , market forces and tenacious global competition can lead to lower prices and broad access over time . behalf of America ' s hepatitis C patients , let ' s repeat that success once more .
